<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502788</url>
  </required_header>
  <id_info>
    <org_study_id>503</org_study_id>
    <secondary_id>U01HL065238</secondary_id>
    <secondary_id>U01HL065238-07</secondary_id>
    <nct_id>NCT00502788</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)</brief_title>
  <acronym>HepC</acronym>
  <official_title>Thalassemia Clinical Research Network - Hepatitis C Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C is one of the most common causes of long-term liver disease in the United States.
      Ribavirin and peginterferon alfa-2a are two medications that are used to treat hepatitis C
      infection. The purpose of this study is to evaluate the safety of these two medications in
      adults with hepatitis C and thalassemia, a type of blood disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C is an inflammation of the liver that is caused by infection with the hepatitis C
      virus. Over time, people may develop liver failure, liver cancer, or cirrhosis, a condition
      in which the liver may become permanently scarred. Ribavirin and peginterferon alfa-2a are
      two medications that are used to treat hepatitis C. Ribavirin stops the hepatitis C virus
      from spreading inside the body, and peginterferon alfa-2a decreases the amount of hepatitis C
      virus in the body. Individuals with thalassemia, an inherited blood disorder that can cause
      anemia, often receive regular blood transfusions as part of their treatment. These
      individuals may have an increased risk of developing hepatitis C as a result of blood
      transfusions received before routine hepatitis C blood screening was available. Treating
      thalassemia patients with standard hepatitis C therapy can be difficult because ribavirin can
      worsen anemia. However, omitting ribavirin then increases the risk of hepatitis C relapse
      following treatment. The purpose of this study is to evaluate the safety of ribavirin and
      peginterferon alfa-2a for treating hepatitis C in adults with thalassemia.

      This study will enroll adults with thalassemia and long-term hepatitis C. Participants will
      attend study visits weekly for 4 weeks, every 2 weeks until Week 24, every 4 weeks until Week
      48, and then every 6 weeks until Week 72. All participants will receive a peginterferon
      alfa-2a injection once a week and ribavirin daily. Participants with the hepatitis C genotype
      1 will receive 48 weeks of treatment; participants with all other genotypes of the disease
      will receive 24 weeks of treatment. A liver biopsy will occur at baseline and Week 48. The
      following will occur at selected study visits: physical exam, blood and urine collection,
      hearing and vision screening, chest x-ray, heart rate monitoring, and questionnaires to
      assess hepatitis C symptoms, quality of life, and depression. Participants with liver iron
      levels greater than 20 mg/g will undergo an echocardiogram ultrasound test every 3 months to
      monitor the heart.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of peginterferon alfa-2a and ribavirin in individuals with thalassemia (measured by changes in liver iron stores and development of iron overload-related complications)</measure>
    <time_frame>Measured at Week 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in hepatic iron concentration from baseline biopsy to follow-up biopsy; relationship of change to baseline level</measure>
    <time_frame>Measured at Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion frequency and volume required to maintain trough Hb 9.0-10.5 g/dL during treatment, as compared to that required in the 6 months prior to hepatitis C treatment</measure>
    <time_frame>Measured at Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulate change in deferoxamine dose; evidence for deferoxamine toxicity during hepatitis C treatment</measure>
    <time_frame>Measured at Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (undetectable hepatitis C virus RNA)</measure>
    <time_frame>Measured at Week 24 or 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained virologic response rate (undetectable hepatitis C virus RNA 24 weeks after the end of treatment) and its association with baseline hepatic iron concentration</measure>
    <time_frame>Measured at Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of viral clearance from serum in the first 4 weeks of treatment, rate of early virologic response at week 12, and each rate's association with sustained virologic response</measure>
    <time_frame>Measured at Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver inflammation and fibrosis scores from baseline to 48 weeks</measure>
    <time_frame>Measured at Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Measured at Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac adverse events, defined as either symptomatic left ventricular dysfunction requiring medication or pathologic arrhythmia requiring medication</measure>
    <time_frame>Measured at Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Measured at Week 72</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Thalassemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Alfa-2a and Ribavirin</intervention_name>
    <description>Patients will be treated with alfa-2a and ribavirin as follows:
Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly.</description>
    <other_name>Human recombinant E. Coli</other_name>
    <other_name>Hoffmann-la Roche</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight &gt; 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of thalassemia

          -  Serum positive for hepatitis C virus RNA by polymerase chain reaction (PCR) test
             (using the Roche COBAS Amplicor hepatitis C virus test)

          -  Hepatitis B surface antigen (HBsAg) negative and HIV negative within the 12 months
             prior to study entry

          -  Liver biopsy showing histologic evidence of active hepatitis (i.e., at least grade 1
             inflammation)

          -  Willing to use acceptable forms of contraception throughout the study

        Exclusion Criteria:

          -  Baseline liver iron concentration greater than 40.00 mg/g dry weight (iron may be
             chelated and the individual re-screened). All people with liver iron levels greater
             than 20.00 mg/g dry weight will be permitted to enroll only if their ejection fraction
             is 55 or greater by echocardiography (ECHO).

          -  Currently participating in other interventional clinical studies

          -  Received interferon-alfa therapy within the 6 months prior to study entry

          -  Liver dysfunction, defined as international normalized ratio (INR) greater than 1.3,
             albumin less than or equal to 3.5g/dL, or serum bilirubin greater than 4.0 mg/dL that,
             in the opinion of the investigator, is not due to Gilbert's syndrome or
             thalassemia-related hemolysis

          -  Other causes of liver disease (e.g., hereditary hemochromatosis, presumed
             drug-associated liver disease, Wilson's disease, obesity [body mass index (BMI)
             greater than 30])

          -  Major psychiatric illness

          -  Neutrophil count less than or equal to 1500/mm3

          -  Platelet count less than or equal to 80,000/mm3

          -  Active alcohol abuse within the 12 months prior to study entry

          -  Use of illicit drugs (e.g., heroin, cocaine, angel dust) within the 2 years prior to
             study entry

          -  Alpha-fetoprotein level greater than 200 ng/mL or evidence of a liver mass lesion by
             either ultrasound, CT scan, or MRI scan that is suspicious for hepatocellular cancer

          -  Kidney insufficiency, as defined by a clinically significant abnormal serum creatinine
             test and confirmed by a creatinine clearance rate of less than 50 mL/min based on
             24-hour urine collection. People with an elevated serum creatinine level must undergo
             a creatinine clearance test.

          -  Diabetes that, in the opinion of the investigator, is not controlled by diet, an oral
             hypoglycemic agent, and/or insulin

          -  Received an organ, limb, or bone marrow transplant

          -  Requires the use of certain long-term medications such as immunosuppressive
             medications (e.g., corticosteroids, methotrexate, azathioprine)

          -  Active systemic autoimmune disorder (e.g., rheumatoid arthritis, systemic lupus)

          -  Diagnosis or treatment of cancer within the 5 years prior to study entry, except for
             localized squamous or basal cell cancers treated by local excision

          -  Any of the following pre-existing conditions that, in the opinion of the investigator,
             would prevent treatment with interferon and/or ribavirin:

               1. unstable heart disease that is not controlled by medication

               2. serious cerebrovascular disease

               3. serious lung disease

          -  History of a seizure disorder that has not been well-controlled by anti-seizure
             medications within the 2 years prior to study entry

          -  Pregnant or breastfeeding

          -  Male partners of women who are pregnant

          -  Any other condition that, in the opinion of the investigator, would prevent study
             participation

          -  Known hypersensitivity to any study drug or their components

          -  Past history of multiple sclerosis, transverse myelitis, optic neuritis, papilledema,
             chorioretinitis, uveitis, or increased ocular pressure/glaucoma

          -  Currently taking hematopoietic growth factors

          -  Currently taking ribavirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maureen Jonas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Childrenâ€™s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital and Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital, Universty Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>WC1E 6HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <name_title>National Heart, Lung, and blood Institute</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

